What's Happening?
The Blood and Cells Advocacy Roster (BCAR), an industry group, is advocating for biopharmaceutical companies to leverage existing blood center infrastructure to scale cell and gene therapies (CGTs). As CGTs transition from treating small cohorts at academic
centers to larger patient populations, a significant bottleneck has emerged in the initial cell collection and delivery process. Historically, this 'first mile' of CGT manufacturing has been handled by clinical research teams at academic medical centers, a model that is proving unscalable, inefficient, and geographically limited for broader commercial use. Blood centers, with their established infrastructure, regulatory compliance, quality systems, and community footprint, are presented as a ready-made solution. They possess experience in leukapheresis, donor recruitment, screening, logistics, and managing cellular starting material for both autologous (patient's own cells) and allogeneic (donor cells) therapies, all under rigorous quality regimes aligned with GMP and GCP expectations.
Why It's Important?
The current reliance on academic medical centers for cell collection is a major impediment to the widespread commercialization and patient access of cell and gene therapies. Many CGT companies have struggled with scaling their manufacturing infrastructure, leading to significant financial challenges and limited patient reach. By integrating blood centers into the CGT supply chain, biopharma companies can tap into a decentralized network that offers greater geographic access, donor diversity, and cost efficiency. This shift would allow clinical sites to focus on patient care and drug delivery, rather than managing complex manufacturing inputs, thereby simplifying clinical site expansion and increasing patient access without requiring new, substantial investments. The standardized protocols and quality systems already in place at blood centers can also facilitate faster technology transfer and ensure product traceability and quality control, which are critical in the highly regulated CGT space.
What's Next?
Organizations like BCAR are actively working to formalize cross-sector collaboration between blood and tissue collection networks, technology providers, and biotherapy stakeholders. The goal is to build a precompetitive, mission-driven ecosystem that optimizes interoperability, standardization, and patient access for CGTs. This involves educating biopharma companies about the capabilities of blood centers and fostering partnerships to develop new donor recruitment strategies and support patient collections in community hospitals or existing donation facilities. As demand for CGTs grows, leveraging and building upon the existing infrastructure of blood centers is seen as the fastest and most cost-effective path to establishing a distributed network capable of supporting the industry's scaling needs. This will require continued collaboration to ensure that blood centers can adapt their services to meet the specific requirements of CGT manufacturing.
Beyond the Headlines
The integration of blood centers into the cell and gene therapy supply chain represents a significant evolution in healthcare logistics and infrastructure. This move could democratize access to advanced therapies, making them available to a much broader patient population beyond major academic medical centers. It also highlights the innovative repurposing of existing healthcare resources to meet emerging medical needs. Ethically, this approach promotes equity in healthcare by reducing geographical barriers to life-saving treatments. Economically, it could drive down the overall cost of CGT manufacturing, making these therapies more affordable and sustainable in the long run. Culturally, it signifies a shift towards a more collaborative and integrated healthcare ecosystem, where different sectors work together to overcome complex challenges in delivering cutting-edge medical innovations. This strategic partnership could ultimately accelerate the pace at which transformative cell and gene therapies reach patients in need.
